drug · small molecule

ZEPZELCA

updated 5mo ago

/ LUR-bi-NEK-ti-din /

by $JAZZ Jazz Pharmaceuticals plc🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and small cell lung carcinoma and 9 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying ZEPZELCA

phase3BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)recruitingn=550
phase3A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancerrecruitingn=531
phase3A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Canceractive not recruitingn=660
phase3Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)completedn=705
phase2Lurbinectedin in FET-Fused Tumorsrecruitingn=63
phase3A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancernot yet recruitingn=530
phase2Lurbinectedin + Doxorubicin In Leiomyosarcomaactive not recruitingn=62
phase3A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancerrecruitingn=540

News(4)

Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survi…
fiercebiotech · 15d ago
Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
raps · 1mo ago
Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory study
Plus news about Caribou, Adial, and the Beneluxa Initiative. 💵 Enliven Therapeutics’ data and raise: The Burlingame, CA-based biotech priced a $400 million offering {$ELVN} Thursday night after sa…
endpoints · 3mo ago
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.
onclive · 4mo ago

brand

ZEPZELCA

trade names

Zepsyre, Zepzelca

generic

LURBINECTEDIN

MOA

12.1 Mechanism of Action Lurbinectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death. Lurbinectedin inhibited human monocyte activity in vitro and reduced macrophage infiltration in implanted tumors in mice.

indication

1 INDICATIONS AND USAGE ZEPZELCA is an alkylating drug indicated: • in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide. ( 1.1 ) • For the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. ( 1.2 ) This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.2 ) 1.1 Extensive-Stage Small Cell Lung Cancer ZEPZELCA, in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide. 1.2 Metastatic Small Cell Lung Cancer ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 2h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

ZEPZELCA

updated 5mo ago

/ LUR-bi-NEK-ti-din /

by $JAZZ Jazz Pharmaceuticals plc🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and small cell lung carcinoma and 9 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying ZEPZELCA

phase3BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)recruitingn=550
phase3A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancerrecruitingn=531
phase3A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Canceractive not recruitingn=660
phase3Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)completedn=705
phase2Lurbinectedin in FET-Fused Tumorsrecruitingn=63
phase3A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancernot yet recruitingn=530
phase2Lurbinectedin + Doxorubicin In Leiomyosarcomaactive not recruitingn=62
phase3A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancerrecruitingn=540

News(4)

Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
MediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survi…
fiercebiotech · 15d ago
Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
raps · 1mo ago
Enliven prices $400M offering; Jazz drug Zepzelca fails confirmatory study
Plus news about Caribou, Adial, and the Beneluxa Initiative. 💵 Enliven Therapeutics’ data and raise: The Burlingame, CA-based biotech priced a $400 million offering {$ELVN} Thursday night after sa…
endpoints · 3mo ago
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.
onclive · 4mo ago

brand

ZEPZELCA

trade names

Zepsyre, Zepzelca

generic

LURBINECTEDIN

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 2h ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

ZEPZELCA

🐶 often sniffed alongside

all catalysts(0)

Trials studying ZEPZELCA

News(4)

Report a data issue

comments(0)

ZEPZELCA

🐶 often sniffed alongside

all catalysts(0)

Trials studying ZEPZELCA

News(4)

Report a data issue

comments(0)